Trial Profile
A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SAR 428926 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 12 Apr 2018 Planned End Date changed from 2 Apr 2018 to 15 Jun 2018.
- 12 Apr 2018 Planned primary completion date changed from 2 Apr 2018 to 15 Jun 2018.